# Etanercept for Wegener's Granulomatosis

> **NCT00005007** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 181 (—)

## Conditions studied

- Wegener's Granulomatosis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00005007
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 181 (—)
- **Last updated:** 2007-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005007, "Etanercept for Wegener's Granulomatosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00005007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*